Combined modality therapy for limited-disease Small Cell Lung Cancer

Luis Raez, Michael A Samuels, Rogerio Lilenbaum

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Small Cell lung Cancer (SCLC) is highly sensitive to chemotherapy and radiotherapy. However, despite initial responses, relapses are common and most patients eventually succumb to this disease. Patients with limited-disease SCLC represent approximately 30% of all patients with SCLC, and are potentially curable when treated with combined chemotherapy and thoracic radiotherapy (TRT). Chemotherapy consists of four cycles of the combination of cisplatin and etoposide (PE). Thoracic radiotherapy should be started with the first or second cycle of chemotherapy, and preferably administered twice daily for 3 weeks. Prophylactic cranial irradiation (PCI) is recommended for patients who achieve a complete response. Surgery is of limited value in SCLC, except in patients who present with a solitary pulmonary nodule. Approximately 20% to 25% of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalCurrent Treatment Options in Oncology
Volume6
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Combined Modality Therapy
Small Cell Lung Carcinoma
Drug Therapy
Radiotherapy
Thorax
Solitary Pulmonary Nodule
Cranial Irradiation
Etoposide
Cisplatin
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined modality therapy for limited-disease Small Cell Lung Cancer. / Raez, Luis; Samuels, Michael A; Lilenbaum, Rogerio.

In: Current Treatment Options in Oncology, Vol. 6, No. 1, 01.01.2005, p. 69-74.

Research output: Contribution to journalArticle

@article{575df76da8ae4e559d951e69c155f038,
title = "Combined modality therapy for limited-disease Small Cell Lung Cancer",
abstract = "Small Cell lung Cancer (SCLC) is highly sensitive to chemotherapy and radiotherapy. However, despite initial responses, relapses are common and most patients eventually succumb to this disease. Patients with limited-disease SCLC represent approximately 30{\%} of all patients with SCLC, and are potentially curable when treated with combined chemotherapy and thoracic radiotherapy (TRT). Chemotherapy consists of four cycles of the combination of cisplatin and etoposide (PE). Thoracic radiotherapy should be started with the first or second cycle of chemotherapy, and preferably administered twice daily for 3 weeks. Prophylactic cranial irradiation (PCI) is recommended for patients who achieve a complete response. Surgery is of limited value in SCLC, except in patients who present with a solitary pulmonary nodule. Approximately 20{\%} to 25{\%} of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation.",
author = "Luis Raez and Samuels, {Michael A} and Rogerio Lilenbaum",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "69--74",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Combined modality therapy for limited-disease Small Cell Lung Cancer

AU - Raez, Luis

AU - Samuels, Michael A

AU - Lilenbaum, Rogerio

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Small Cell lung Cancer (SCLC) is highly sensitive to chemotherapy and radiotherapy. However, despite initial responses, relapses are common and most patients eventually succumb to this disease. Patients with limited-disease SCLC represent approximately 30% of all patients with SCLC, and are potentially curable when treated with combined chemotherapy and thoracic radiotherapy (TRT). Chemotherapy consists of four cycles of the combination of cisplatin and etoposide (PE). Thoracic radiotherapy should be started with the first or second cycle of chemotherapy, and preferably administered twice daily for 3 weeks. Prophylactic cranial irradiation (PCI) is recommended for patients who achieve a complete response. Surgery is of limited value in SCLC, except in patients who present with a solitary pulmonary nodule. Approximately 20% to 25% of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation.

AB - Small Cell lung Cancer (SCLC) is highly sensitive to chemotherapy and radiotherapy. However, despite initial responses, relapses are common and most patients eventually succumb to this disease. Patients with limited-disease SCLC represent approximately 30% of all patients with SCLC, and are potentially curable when treated with combined chemotherapy and thoracic radiotherapy (TRT). Chemotherapy consists of four cycles of the combination of cisplatin and etoposide (PE). Thoracic radiotherapy should be started with the first or second cycle of chemotherapy, and preferably administered twice daily for 3 weeks. Prophylactic cranial irradiation (PCI) is recommended for patients who achieve a complete response. Surgery is of limited value in SCLC, except in patients who present with a solitary pulmonary nodule. Approximately 20% to 25% of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=13544276539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544276539&partnerID=8YFLogxK

M3 - Article

C2 - 15610716

AN - SCOPUS:13544276539

VL - 6

SP - 69

EP - 74

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -